Exchange: NASDAQ
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:00 PM ET 5/24/2013
Last 10 Quotes:
What's This?
| Fiscal Q1 Ending 03/13 |
Fiscal Q4 Ending 12/12 |
Fiscal Q3 Ending 09/12 |
Fiscal Q2 Ending 06/12 |
Fiscal Q1 Ending 03/12 |
|
Sales/Revenue |
2,085 | 1,806 | 2,874 | 2,684 | 2,350 |
Depreciation & Amortization Expense |
319 | 309 | 306 | 300 | 292 |
SG&A Expense |
21,445 | 21,499 | 12,016 | 17,033 | 17,906 |
Research & Development |
13,764 | 12,515 | 12,850 | 11,376 | 12,405 |
Other SG&A |
7,681 | 8,984 | -834 | 5,657 | 5,501 |
Other Operating Expense |
0 | 0 | 0 | 0 | 0 |
Unusual Expense |
1,200 | 0 | 0 | 0 | 0 |
Non Operating Income/Expense |
14 | -38 | -196 | 63 | -122 |
Equity in Affiliates (Pretax) |
NA | NA | 0 | 0 | 0 |
Interest Expense |
32 | 586 | 589 | 589 | 587 |
Gross Interest Expense |
32 | 586 | 589 | 589 | 587 |
Pretax Income |
-20,825 | -20,543 | -17,791 | -15,110 | -16,505 |
Income Tax |
0 | 0 | 0 | 0 | 0 |
Equity in Affiliates |
0 | 0 | 0 | 0 | 0 |
Consolidated Net Income |
-20,825 | -20,543 | -17,791 | -15,110 | -16,505 |
Minority Interest Expense |
0 | 0 | 0 | 0 | 0 |
Net Income |
-20,825 | -20,543 | -17,791 | -15,110 | -16,505 |
Extraordinaries & Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Extra Items & Gain/Loss Sale Of Assets |
0 | 0 | 0 | 0 | 0 |
Cumulative Effect - Accounting Chg |
0 | 0 | 0 | 0 | 0 |
Discontinued Operations |
0 | 0 | 0 | NA | NA |
Net Income After Extraordinaries |
-20,825 | -20,543 | -17,791 | -15,110 | -16,505 |
Preferred Dividends |
0 | 0 | 0 | 0 | 0 |
Net Income available to Common |
-20,825 | -20,543 | -17,791 | -15,110 | -16,505 |
Operational EPS |
-0.11 | -0.11 | -0.10 | -0.09 | -0.11 |
EPS (basic) |
-0.11 | -0.11 | -0.10 | -0.09 | -0.11 |
EBITDA |
-19,360 | -19,693 | -16,791 | -14,649 | -10,055 |
Depreciation & Amortization Expense |
319 | 309 | 306 | 300 | 292 |
Common Shares Outstanding |
182,847 | 180,685 | 177,870 | 167,697 | 155,431 |
Basic Shares Outstanding |
182,847 | 180,685 | 177,870 | 167,697 | 155,431 |
Diluted Shares Outstanding |
182,847 | 180,685 | 177,870 | 167,697 | 155,431 |
Diluted EPS after Extraordinary Items |
-0.11 | -0.11 | -0.10 | -0.09 | -0.11 |
Discont. Operations Per Share |
0 | 0 | 0 | 0 | 0 |
Continued operations EPS |
-0.11 | -0.11 | -0.10 | -0.09 | -0.11 |
*Figures in thousands of U.S. Dollars except shares outstanding.
